1994

• Enable Medical founded

2000

• AtriCure established

2001

• AtriCure Bipolar Ablation System cleared
  • First-generation Isolator Clamp (LHP1) cleared

2002

• AtriCure Bipolar Ablation System released to market including second-generation Bipolar Ablation Clamp (LHP2) and second-generation Ablation Sensing Unit (ASU2)
• AtriCure received its first CE Mark approval that included the Bipolar Ablation System
• Washington University published the seminal paper on AtriCure’s Bipolar Radiofrequency Technology

2003

• Foundational patent 6,517,536 and 6,546,935 issued for “Device and Methods for Transmural Ablation”
• First commercial sale that included the Bipolar Ablation Clamp

2004

• Lumitip™ Dissector released to market
• First international sale that was sold to Belgium

2005

• Isolator® Transpolar™ Pen (MAX1) released to market
• AtriCure listed on NASDAQ
• AtriCure opened its European office in the Netherlands

2006

• Isolator® Transpolar™ Long Pen (MAX5) released to market
• Isolator® Transpolar™ System released to market including the Isolator Clamps (OLL1, EMR1 and EML1)

2007

• AtriCure Synergy Bipolar Ablation System released to market including the Isolator Synergy Clamps (OLL2, OSL2, EMR2 and EML2) along with AtriCure Switch Matrix (ABS3)
• First AtriClip device implanted
• AtriCure entered the Cryosurgical market

2008

• Isolator Coolrail® Linear Pen released to market
• ABLATE Clinical Trial enrollment initiated
• EXCLUDE Clinical Trial enrollment initiated
• Continued to grow international presence by selling products in over 25 countries

2009

• CRYO1 Cryoablation Probe released to market
• ORLab® System released to market
• DEEP (Hybrid) Clinical Trial enrollment initiated

2010

• AtriClip Left Atrial Appendage (LAA) Exclusion System released to market
  • AtriClip ACH1 device released to market
• CRYO2 cryoICE® Cryoablation Probe released to market
• Multifunctional Linear Pen released to market

2011

• AtriCure Cryo Module System released to market
• Isolator Synergy System approved for treatment of persistent or long-standing persistent atrial fibrillation
• Isolator Synergy Access Clamp released to market

2012

• AtriClip PRO® device released to market
• DEEP (Staged) Clinical Trial enrollment initiated
• Maze IV Training Program initiated
• AtriCure hosted 25th Anniversary of the Cox Maze Procedure
• Over 100,000 ablations performed

2013

• Established Professional Education Program
• AtriCure expanded the Maze IV Training Program to Europe
• AtriCure acquired Endoscopic Technologies, Inc. (Estech)

2014

• AtriClip FLEX device (ACH2) released to market
• CRYO3 cryoICE Cryoablation Probe and AtriCure Cryo Module Version 6 (ACM V6) released to market
• ABLATE-PAS Clinical Trial completes enrollment
• DEEP (Pivotal) Clinical Trial enrollment initiated
• Completed requirement to train U.S. surgeons on Synergy Clamp per FDA mandate
• Minneapolis office opened
• Over 150,000 ablations performed

2015

• cryoICE® probe made available for Cryo Nerve Block applications
• CEASE-AF Clinical Trial enrollment initiated
• Dr. James L. Cox American Association for Thoracic Surgery (AATS) Fellowship Training Program established
• Introduced Advanced Ablation weekend training courses
• AtriCure acquired nContact Surgical, LLC.
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2015 by Cincinnati Enquirer
• New headquarters opened in Mason, Ohio, near Cincinnati
• 200,000 ablations performed and 50,000 AtriClip devices sold
• Continued to grow international presence by selling products in over 50 countries

2016

• AtriClip PRO2® device released to market
• cryoFORM® Probe released to market
• ATLAS Clinical Trial enrollment initiated
• FROST Clinical Trial enrollment initiated
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2016 by Cincinnati Enquirer
• The Society of Thoracic Surgeons (STS) 2017 Clinical Practice Guidelines recommend Afib ablation treatment
• Gained approval for the AtriClip® products and cryoICE® platform in Japan

2017

• AtriClip PRO•V® device released to market
• Introduced Nurse Continuing Education Unit (CEU) Course for Ablation and Left Atrial Appendage Management
• Heart Rhythm Society (HRS) provide Class I recommendation
• Over 250,000 ablations performed and surpassed 100,000 AtriClip devices sold worldwide

2018

• AtriClip® FLEX•V® released to market
• CONVERGE IDE Clinical Trial completes enrollment
• AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2018 by Cincinnati Enquirer

2019

• cryoICE cryoSPHERE® Probe released to market
• Received expanded labeling claims for AtriClip devices
• ICE-AFIB Clinical Trial enrollment initiated
• First national Fellows Concomitant Ablation Training Course led by Northwestern Faculty Drs. McCarthy and Cox
• AtriCure acquired SentreHEART, Inc.
• Facility expansions at headquarters and European location
• The Society of Thoracic Surgeons (STS) endorses AtriCure’s Advanced Ablation Courses in the United States
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2019 by Cincinnati Enquirer
• Over 2,500 healthcare professionals trained, more than 350,000 ablations performed, and surpassed 200,000 AtriClip devices sold worldwide

2020

• MO100000 marked the 100,000th production build
• aMAZE Clinical Trial completes enrollment
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2020 by Cincinnati Enquirer
• Minnetonka office named Top Workplaces 2020 National Standard Setter by Minneapolis Star Tribune

2021

• Received expanded labeling for Cryo Nerve Block Therapy
• EPi-Sense^® Guided Coagulation System approved for treatment of long-standing persistent atrial fibrillation
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2021 by Cincinnati Enquirer
• AtriCure surpasses one million devices produced

2022

• Isolator^® Synergy™ EnCompass^® Clamp released to market
• HEAL-IST™ Clinical Trial enrollment initiated
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2022 by Cincinnati Enquirer
• Minnetonka office named Top Workplaces 2022 National Standard Setter by Minneapolis Star Tribune
• Amsterdam office earned a Great Place to Work Award Netherlands 2022
• AtriCure wins 2022 National Association of Corporate Directors (NACD) Diversity, Equity, & Inclusion Award

2023

• LeAAPS Clinical Trial enrollment initiated
• EPi-Sense ST™ device released to market
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2023 by Cincinnati Enquirer
• Minnetonka office named Top Workplaces 2023 National Standard Setter by Minneapolis Star Tribune
• Amsterdam office earned a Great Place to Work Award Netherlands 2023 for the second time in company history
• Mike Carrel named the Top Large Business Leader in the Greater Cincinnati region (as part of Top Workplaces awards)
• Multifunctional Ablation Generator (MAG) released to market
• Over 1 million patients treated and surpassed 500,000 AtriClip devices sold worldwide

2024

• cryoSPHERE®+ Probe released to market
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2024 by Cincinnati Enquirer
• Minnetonka office named Top Workplaces 2024 by Minneapolis Star Tribune
• AtriClip® FLEX-Mini™ device released to market
• cryoSPHERE® MAX Probe released to market
• Amsterdam office earned a Great Place to Work Award Netherlands 2024 for the third time in company history. The Great Place to Work Award 2024 was also awarded for Australia and United Kingdom

2025

• EPi-Ease™ device released to market
• AtriCure earned a spot on U.S. News & World Report’s 2025–2026 Best Companies to Work For list, for the first time in company history
• Mason Headquarters earned Greater Cincinnati’s Top Workplaces 2025 by Cincinnati Enquirer
• Minnetonka office named Top Workplaces 2025 by Minneapolis Star Tribune
• AtriClip PRO-Mini® device released to market